

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(currently amended)** A method for screening for compounds safe for gastric mucosa, comprising:
 - preparing liposomes_s, serving as a cell membrane model_s, that ~~[[is]]~~ are formed of a phospholipid and encapsulate~~[[s]]~~ a fluorescent dye;
 - allowing a test compound to react with the liposomes; and
 - evaluating the leakage of the fluorescent dye from the liposomes.
2. The method for screening according to claim 1, wherein the phospholipid for use in the cell membrane model is selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine, and cardiolipin.
3. **(currently amended)** The method for screening according to claim 1 ~~[[or 2]]~~, wherein evaluation of the leakage of the fluorescent dye comprises measuring fluorescence emitted from the dye at an excited wavelength.
4. **(currently amended)** The method for screening according to ~~any of claims 1 to 3~~ claim 1, wherein the fluorescent dye is selected from the group consisting of calcein, rhodamine, and fluorescein derivatives.

5. **(currently amended)** The method for screening according to ~~any of claims 1 to 3~~ claim 4, wherein the fluorescent dye is calcein.

6. The method for screening according to claim 5, wherein the calcein leakage is determined by measuring fluorescence at 520 nm.

7. **(currently amended)** The method for screening according to ~~any of claims 1 to 6~~ claim 1, wherein the test compound is an anti-inflammatory compound.

8. The method for screening according to claim 7, wherein the anti-inflammatory compound is a nonsteroidal anti-inflammatory compound or a steroid compound.

9. **(currently amended)** The method for screening according to ~~any of claims 1 to 6~~ claim 1, wherein the test compound is a compound that acts to protect gastric mucosa.

10. **(currently amended)** An anti-inflammatory compound safe for gastric mucosa, obtained by the method for screening according to ~~claim 7 or 8~~ claim 7, or a salt thereof.

11. A gastric mucosa-protecting material, obtained by the method for screening according to claim 9.

12. A liposome serving as a cell membrane model for use in the screening of compounds having membrane toxicity to gastric mucosa, the liposome being formed of a phospholipid and encapsulating a fluorescent dye.

13. The liposome according to claim 12, wherein the fluorescent dye is selected from the group consisting of calcein, rhodamine, and fluorescein derivatives.

14. The liposome according to claim 12, wherein the phospholipid for use in the cell membrane model is selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine, and cardiolipin.